Evidence map›Paper›PMID 41307146›Full record

Observational studyCirculation. Heart failure2026

Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.

Ashley Park, Temesgen E Andargie, Xin Tian, Michael Keller, Isabella Cavagna, Neelam Redekar, Tom Hill, Hyesik Kong, Woojin Park, Xinyue Zhao and 8 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ashley Park *Laboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0009-0007-8149-2121
Temesgen E Andargie *Laboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0003-2888-1316
Xin TianOffice of Biostatistics Research, NHLBI (X.T.), National Institutes of Health, Bethesda, MD.ORCID 0000-0003-1896-2462
Michael KellerLaboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6695-4582
Isabella CavagnaAdvanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA (I.C., D.T., P.S.).ORCID 0009-0003-4968-647X
Neelam RedekarIntegrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases (N.R., T.H.), National Institutes of Health, Bethesda, MD.ORCID 0000-0002-4819-9034
Tom HillIntegrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases (N.R., T.H.), National Institutes of Health, Bethesda, MD.
Hyesik KongLaboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7540-2045
Woojin ParkLaboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0001-9982-0057
Xinyue ZhaoDepartment of Statistics, George Washington University, Washington, DC (X.Z.).
Prasanthy BalasubramanianDivision of Infectious Diseases, Department of Medicine (P.B., A.K.), Johns Hopkins University School of Medicine, Baltimore, MD.
Daniel TangAdvanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA (I.C., D.T., P.S.).ORCID 0000-0001-7142-1783
Andrew KarabaDivision of Infectious Diseases, Department of Medicine (P.B., A.K.), Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-2785-317X
Moon JangLaboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0002-1657-2877
Michael A SolomonCritical Care Medicine, Clinical Center (A.P., M.K., M.A.S.), National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7400-6614
Hannah ValantineCardiovascular Medicine Division, Stanford University, Palo Alto, CA (H.V.).ORCID 0000-0002-2948-9503
Palak ShahAdvanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA (I.C., D.T., P.S.).ORCID 0000-0001-8175-168X
Sean Agbor-EnohLaboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (A.P., T.E.A., M.K., H.K., W.P., M.J., S.A.-E.), National Institutes of Health, Bethesda, MD.ORCID 0000-0002-9380-9161

Funding

Cell-free DNA to detect transplant rejectionZIAHL006268 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI AGBOR-ENOH, SEAN · 2021 to 2025
$8.8M
Intramural NIH HHS Z99 HL999999Intramural NIH HHS ZIA HL006268Intramural NIH HHS ZIA HL006274
6 · The paper itself

Abstract

backgroundAdverse events after durable left ventricular assist devices (LVADs) pose a challenge to survival. However, there are limited risk stratification approaches. Plasma cell-free DNA (cfDNA) offers potential as a biomarker for assessing end-organ injury and risk stratification.

methodsThe study included a multicenter prospective cohort of patients with heart failure with and without LVAD (cohort 1), a separate cohort of patients with heart failure with paired samples before and after LVAD (cohort 2) implantation, and a comparator group of healthy controls. Nuclear cfDNA (ncfDNA) and mitochondrial cfDNA were quantified by digital droplet polymerase chain reaction. Tissue-specific cfDNA was identified using whole-genome bisulfite sequencing. Differences in cfDNA levels by LVAD use were assessed with the Wilcoxon rank-sum test or the paired

resultsCohort 1 had 76 patients with LVAD and 144 without LVAD. Cohort 2 had 40 patients with LVAD with samples before and after LVAD. ncfDNA levels were 4-fold higher (9794 versus 2386 copies/mL;

conclusionsLVAD implantation was associated with reductions in systemic and tissue-specific cfDNA levels. cfDNA levels offer promise for improving risk stratification of LVAD candidates for post-LVAD outcomes.

Indexed as

Cell-Free Nucleic AcidsHeart-Assist DevicesHeart FailureAgedBiomarkersFemaleHumansMaleMiddle AgedProspective StudiesRisk AssessmentTreatment OutcomeBiomarkersCell-Free Nucleic Acidsbiomarkerscell-free nucleic acidsepigenomicsheart failureliquid biopsy

Identifiers

PMID41307146
PMCPMC12964431

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.